Vertex Pharmaceuticals Incorporated

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 1,666 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• Vertex's own equity investments are disclosed only as two combined balance-sheet totals, never broken into named investees, in both the FY2025 10-K and the Q2 2026 10-Q: (1) 'Corporate equity securities' (publicly traded, marketable, fair value through other comprehensive income) were $16.6 million at 31 Dec 2025 and $11.9 million at 30 Jun 2026; (2) 'equity investments without readily determinable fair values' (private, non-marketable), recorded in Other assets, were $81.5 million at 31 Dec 2025, $64.8 million at 31 Dec 2024, and $80.1 million at 30 Jun 2026. Neither filing names a single company inside either balance, so per the brief's rule on combined balances, no holding row is recorded for either: the combined figures are reported here rather than invented as sized positions.
• Vertex's collaboration and license agreements with CRISPR Therapeutics AG (CASGEVY joint development and commercialization agreement), Entrada Therapeutics, and Moderna are commercial partnerships, not equity stakes: neither the FY2025 10-K nor the Q2 2026 10-Q states that Vertex purchased or holds shares of any of these companies. Per the brief's caution, a collaboration or licence agreement is not converted into an equity holding absent an explicit statement that shares were bought. Searched terms 'equity method', 'equity securities', 'strategic investment', 'unconsolidated', 'non-marketable', 'CRISPR', 'Verve', 'Entrada', 'Arbor', 'TreeFrog', 'Septerna', and 'Orna' across both filings; only Entrada, Moderna and CRISPR returned hits, and all were collaboration-agreement references, not equity-purchase disclosures. 'Verve', 'TreeFrog' and 'Septerna' returned no hits in either filing.
• During Q2 2026, Vertex received $75.5 million cash following conversion of a note receivable held from a privately-held company that was subsequently acquired, recognizing a $48.7 million realized gain. This was a debt instrument (a note), not an equity holding, and it converted to cash within the quarter, so it is not reported as a holding.
• Vertex has a single class of common stock ($0.01 par value, one vote per share) and no dual-class or founder-control structure; insider ownership is immaterial (the 19-person director-and-officer group holds under 0.2% of shares outstanding).
• Register uses each institutional manager's own Q2 2026 Form 13F-HR (period 30 Jun 2026), not the Q1 2026 (31 Mar 2026) VRTX.json register snapshot, which was used only as a shopping list of which managers to look up, per the task instructions.
• Vanguard Rule: Vanguard Group Inc (CIK 0000102909) filed Form 13F-NT (notice, no holdings) for the quarter ended 30 June 2026; its Vertex position is instead reported by two successor entities, Vanguard Capital Management LLC and Vanguard Portfolio Management LLC, which are summed into one 'The Vanguard Group' row rather than listed separately or omitted. This is the notice case, not the case where the parent itself reports holdings.
• Capital Group is three separately-filing entities (Capital World Investors, Capital International Investors, Capital Research Global Investors), all of which hold Vertex stock in their own Q2 2026 13F-HRs; summed into one 'Capital Group' row with the three entities and CIKs named in that row's method_note, per the task instructions. This is explicitly not the Vanguard successor case.
• The 2026 DEF 14A's own 5%-holder table (based on Schedule 13G/13G-A filings dated Dec 2024 through Feb 2026, all older than the Q2 2026 13F record date used elsewhere in this register) shows: Capital World Investors 28,739,975 shares (11.3%), The Vanguard Group 22,281,729 shares (8.8%), BlackRock, Inc. 21,881,203 shares (8.6%), Capital Research Global Investors 17,319,044 shares (6.8%). These are materially close to, but not identical to, the Q2 2026 13F figures used in the register (differences consistent with position changes and different measurement dates rather than a data error); the register uses the fresher, more precise 13F data throughout instead of the proxy's 13G-sourced figures.
• No Schedule 13D or fresh 13G filing on Vertex common stock was found in the EDGAR SC 13 filing feed for CIK 0000875320 more recent than April 2024 in that feed (the proxy's own more recent 13G/A citations, dated Feb 2025 and Feb 2026, were not independently re-verified as separate filings within the time budget; see unknowns).
• Self-gate check: summing the register rows that are neither aggregate containers nor rolled-up members (11 institutional 13F rows plus the standalone former-officer Stuart A. Arbuckle) gives 133,817,901 shares against 253,460,924 shares outstanding, or 52.80%, within the brief's 15 to 55 percent tolerance band, at the high end because Vertex is heavily institutionally owned and Capital Group alone holds nearly 20% of the company.